Skip to Content
Søk Menu

High lights from ASCO about prostate and kidney cancer

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Laurence Albiges

Triplets frontline therapy increases PFS for patients with previously untreated advanced renal-cell carcinoma

/ Laurence Albiges
Nyrekreft Play the Video 8:54
Neal Shore

A long-term benefit of darolutamide for patients with nmCRPC

/ Neal Shore
ProstatakreftASCOGU23 Play the Video 4:50
Daniel Petrylak

Enfortumab vedotin as neoadjuvant treatment for MIBC

/ Daniel Petrylak
ProstatakreftASCOGU23 Play the Video 3:04
Ahmed Zedan

Inverse correlation between natural killer cell and treatment with enzalutamide

/ Ahmed H. Zedan
ProstatakreftASCOGU23 Play the Video 9:46
Simon Crabb

CAPItello-280 trial aims to confirm findings from ProCAID trial.

/ Simon Crabb
ProstatakreftASCOGU23 Play the Video 6:32

New improvement of PFS in first-line treatment of advanced Renal-Cell carcinoma

/ BestPractice Nordic
NyrekreftASCOGU23

Darolutamide – A viable long-term treatment for nmCRPC

/ BestPractice Nordic
ProstatakreftASCOGU23
Lars Dyrskjøt Andersen

The clinical value of circulating tumor DNA in renal cancer

/ Lars Dyrskjøt Andersen
NyrekreftESMO22 Play the Video 5:46
Daniel Heinrich

Prostatakreft – høydepunkter fra ESMO 2022

/ Daniel Heinrich
ProstatakreftESMO22 Play the Video 4:43
Back to top